Israeli biopharmaceutical company Aspireo Pharmaceuticals’ acromegaly treatment, Somatoprim, has gained a positive opinion from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA).

If the EMA grants the orphan drug status, Aspireo will gain ten years of marketing exclusivity for Somatoprim in the European Union, and reduced regulatory fees.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Aspireo CEO Carsten Dehning said the agency’s recommendation is a key milestone in the drug’s development.

"If the EMA grants the orphan drug status, Aspireo will gain ten years of marketing exclusivity for Somatoprim in the European Union, and reduced regulatory fees."

"By this resolution, EMA recognises the potential of Somatoprim to offer significant medical benefit over existing treatments for acromegaly and it supports our efforts to provide valuable treatment alternatives for the many patients that could benefit from it," Dehning said.

"The ongoing clinical Phase Ib and Phase IIa studies are expected to support the claim that Somatoprim offers an effective and safe treatment for acromegaly patients."

See Also:

The proprietary somatostatin analog (SSA) is based on a novel amino acid composition, which demonstrated a distinctive receptor binding and pharmacological profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Somatoprim has demonstrated reduced adverse effects on the gastrointestinal tract and glucose metabolism, thereby achieving improved side effect profile compared to current SSA therapies.

When the growth hormone secretion was assessed in cultured human somatotroph adenoma tissue treated with Somatoprim, the increased response rate of acromegalic patients to SSA therapy was observed.

At present Somatoprim is in Phase I/II of clinical development, while Phase Ib and Phase IIa studies are being conducted in Switzerland and the Ukraine respectively.